|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.62/1.10
|
企业价值
7.27M
|
资产负债 |
每股账面净值
4.43
|
现金流量 |
现金流量率
--
|
损益表 |
收益
431.38K
|
每股收益
0.23
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/25 02:02 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. |